The potential health impact of prospective Strep A vaccines: a modeling study
Giannini, F.; Cannon, J. W.; Cadarette, D.; Bloom, D. E.; Moore, H. C.; Carapetis, J.; Abbas, K.
Show abstract
The World Health Organization published the preferred product characteristics for a Group A Streptococcus (Strep A) vaccine in 2018. Based on these parameters for the age of vaccination, vaccine efficacy, duration of protection from vaccine-derived immunity, and vaccination coverage, we developed a static cohort model to estimate the projected health impact of Strep A vaccination at the global, regional, and national levels and by country-income category. We used the model to analyse six strategic scenarios. Based on Strep A vaccine introduction between 2022 and 2034 for the primary scenario, we estimated vaccination at birth for 30 vaccinated cohorts could avert 2.5 billion episodes of pharyngitis, 345 million episodes of impetigo, 1.3 million episodes of invasive disease, 24 million episodes of cellulitis, and 6 million cases of rheumatic heart disease globally. Vaccination impact in terms of burden averted per fully vaccinated individual is highest in North America for cellulitis and in Sub-Saharan Africa for rheumatic heart disease.
Matching journals
The top 5 journals account for 50% of the predicted probability mass.
Similar papers in this journal
- COVID-19 impact on routine immunisations for vaccine-preventable diseases: Projecting the effect of different routes to recovery 95%
- Modelling of COVID-19 vaccination strategies and herd immunity, in scenarios of limited and full vaccine supply in NSW, Australia 95%
- mRNA-based COVID-19 booster vaccination is highly effective and cost-effective in Australia 95%
Similar papers in this journal
- The potential economic impact of the updated COVID-19 mRNA fall 2023 vaccines in Japan 95%
- COVID-19 vaccine uptake and effectiveness by time since vaccination in the Western Cape province, South Africa: An observational cohort study during 2020-2022 95%
- Predicting the epidemiological effects in the United Kingdom of moving from PCV13 to PCV15 in the routine pediatric 1+1 vaccination schedule 94%
Similar papers in this journal
Similar papers in this journal
- Benefit-Risk Assessment Of COVID-19 Vaccine, Mrna (Mrna-1273) For Males Age 18-64 Years 96%
- Assessing the feasibility of Phase 3 vaccine trials against Marburg Virus Disease: a modelling study 94%
- Evaluation of statistical models of carriage to predict the impact of the 10-valent pneumococcal conjugate vaccine on invasive pneumococcal disease in Nigeria 93%
"Similar papers" are the closest papers from that journal in the model's embedding space. They show what the match is built on, but the ranking comes mostly from a classifier over the whole training set, not from these examples alone.